Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
60 pending office actions • 30 art units • 57 examiners • 0 of 60 (0%) have an AI response strategy ready • 40 patents granted in the last 365 days
Boehringer Ingelheim International GmbH has a significant presence in the Biotechnology & Pharmaceuticals technology area with 59 pending office actions. These actions are distributed across 56 distinct examiners, showing that the company rarely encounters the same examiner twice across its current pending load. This high level of examiner diversity is matched by a broad technical footprint across 29 distinct art units. The company must manage a vast array of examiner interactions and art unit specificities to advance its 59 pending office actions.
SHIAO, YIH-HORNG is the busiest examiner for the company, yet only manages 2 pending office actions. This highlights the decentralization of the portfolio, where 56 distinct examiners are responsible for the 59 pending office actions. Navigating 29 distinct art units requires the company to maintain expertise across a wide array of pharmaceutical and biotechnological examination standards. The low concentration of cases per examiner, with even the busiest examiner only holding 2 pending office actions, suggests a highly varied prosecution environment across the 29 distinct art units.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (7%) |
| §103 only | 9 (15%) |
| §102 only | 2 (3%) |
| §112 only | 9 (15%) |
| Double-patenting only | 3 (5%) |
| Double-patenting + other | 14 (23%) |
| Multi-statute (no §101) | 19 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, YIH-HORNG | 2 | 72.5% | +75.9% |
| CRAIGO, BAHAR ALAWI | 2 | 47.1% | +27.3% |
| HAVLIN, ROBERT H | 2 | 51.5% | +28.1% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
| DAKKAK, JIHAD | 1 | 49.3% | +46.0% |
| GONG, KRIS HANYU | 1 | 25.7% | +47.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 44d overdue |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | SHIN, DANA H | 23d overdue |
| 17701009 | INHALER | GONG, KRIS HANYU | 3d overdue |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 30d |
| 18666911 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | REDWOOD, CHRISTOPHER EVAN | — |
| 18594627 | SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | SHIAO, YIH-HORNG | — |
| 18578118 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | CRAIGO, BAHAR ALAWI | — |
| 18537432 | SOLID DISPERSIONS COMPRISING AMORPHOUS PIMOBENDAN AND ONE OR MORE STABILIZING POLYMERS | BREDEFELD, RACHAEL EVA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17701009 | INHALER | GONG, KRIS HANYU | 3d overdue |
| 18666922 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | SHIAO, YIH-HORNG | — |
| 18594627 | SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | SHIAO, YIH-HORNG | — |
| 18578118 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | CRAIGO, BAHAR ALAWI | — |
| 18537432 | SOLID DISPERSIONS COMPRISING AMORPHOUS PIMOBENDAN AND ONE OR MORE STABILIZING POLYMERS | BREDEFELD, RACHAEL EVA | — |
| 18252590 | NEW FELINE HERPES VIRUS VACCINE | PARKIN, JEFFREY S | — |
| 17792269 | CONNECTING ARRANGEMENT, CONNECTING SYSTEM, CONTAINER AND CONTAINER SYSTEM | DAKKAK, JIHAD | — |
| 18589552 | New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1624 | 3 |
| 1699 | 3 |
| 1671 | 2 |
| 1611 | 2 |
| 1675 | 2 |
| 1635 | 2 |
| 1641 | 2 |
| 3786 | 1 |
| 3781 | 1 |
| 3785 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19068745 | ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS | HAUK TEODORO, PRICILA NMN | — | §103 | Non-Final OA | — | Pending | Mar 03, 2025 |
| 18666911 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | REDWOOD, CHRISTOPHER EVAN | — | §102§103§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18666922 | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan | SHIAO, YIH-HORNG | — | §102§112DP | Non-Final OA | — | Pending | May 17, 2024 |
| 18594627 | SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | SHIAO, YIH-HORNG | — | §102§103§112 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18578205 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | SAMSELL, RILLA MARIE | 1624 | §103DP | Final Rejection | — | Pending | Jan 10, 2024 |
| 18578118 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | CRAIGO, BAHAR ALAWI | 1699 | §102§103§112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18537432 | SOLID DISPERSIONS COMPRISING AMORPHOUS PIMOBENDAN AND ONE OR MORE STABILIZING POLYMERS | BREDEFELD, RACHAEL EVA | 3786 | §103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18252590 | NEW FELINE HERPES VIRUS VACCINE | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | — | Pending | May 11, 2023 |
| 17792269 | CONNECTING ARRANGEMENT, CONNECTING SYSTEM, CONTAINER AND CONTAINER SYSTEM | DAKKAK, JIHAD | 3781 | §103 | Final Rejection | — | Pending | Jul 12, 2022 |
| 17701009 | INHALER | GONG, KRIS HANYU | 3785 | §102§103§112 | Final Rejection | 3d overdue | Pending | Mar 22, 2022 |
| 19054649 | ATTENUATED BORDETELLA BRONCHISEPTICA STRAINS, ORAL VACCINES CONTAINING THE ATTENUATED STRAINS, AND METHODS OF MAKING & USE THEREOF | GRASER, JENNIFER E | — | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2025 |
| 18003056 | COMBINATION PORCINE VACCINE | FOLEY, SHANON A | 1671 | §103 | Non-Final OA | 31d overdue | Pending | Dec 22, 2022 |
| 18989164 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | GREENE, IVAN A | — | §102§103§112Other | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18872318 | HSD17B13 INHIBITORS | SAEED, KAMAL A | — | §112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18951962 | GPR88-RECEPTOR-AGONIST | WHITE, DAWANNA SHAR-DAY | — | §112 | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18947116 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | KIM, SEONG JONG | — | §102§103DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18808311 | BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES | GAO, ASHLEY HARTMAN | 1678 | §103§112 | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18801886 | Cardiosafe Antidiabetic Therapy | BAEK, BONG-SOOK | — | §102§103Other | Final Rejection | — | Pending | Aug 13, 2024 |
| 18800173 | CARDIO- AND RENOSAFE ANTIDIABETIC THERAPY | KOSTURKO, GEORGE W | — | §102DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18789814 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | NOTTINGHAM, KYLE GREGORY | — | §112 | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18789815 | PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | MCKOY, QUINCY ANDRE | — | DP | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18785078 | PROCESS FOR THE MANUFACTURE OF A HER2 INHIBITOR | OTTON, ALICIA L | — | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18728837 | METHOD FOR STRUCTURE ELUCIDATION | MITCHELL, NATHAN A | — | §101§102§103§112 | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18746567 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | LOVE, TREVOR M | 1611 | §103 | Final Rejection | 28d overdue | Pending | Jun 18, 2024 |
| 18706144 | HETEROCYCLIC COMPOUNDS AS STING ANTAGONISTS | RICCI, CRAIG D | 1611 | §112 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18700748 | TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS | CHENG, KAREN | 1623 | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18695414 | QUANTIFICATION METHOD OF POLYSORBATE IN AQUEOUS FORMULATIONS | SODERQUIST, ARLEN | — | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18691241 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | BURKETT, DANIEL JOHN | 1624 | §112DP | Final Rejection | — | Pending | Mar 12, 2024 |
| 18597314 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS USING AN SGLT-2 INHIBITOR AND A NEUROLEPTIC AGENT | BERRY, LAYLA D | 1693 | §103 | Final Rejection | 66d overdue | Pending | Mar 06, 2024 |
| 18589552 | New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases | HAVLIN, ROBERT H | — | §103§112Other | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18686991 | METHOD OF DETERMINING A FUTURE COLOR VALUE OR CORRESPONDING PROPERTY AND ARRANGEMENT THEREFOR | GUTIERREZ, GISSELLE M | 2884 | §112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18585280 | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | HAVLIN, ROBERT H | — | §103Other | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18423352 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | FONTAINHAS, AURORA M | — | §102§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18579526 | IDENTIFICATION OF COMMON TUMOR-SPECIFIC T CELL RECEPTORS AND ANTIGENS | LANDSMAN, ROBERT S | — | §103§112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18542910 | PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN | ONDACHI, PAULINE WANJIKU MUCH | 1627 | §102§103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18561823 | A METHOD AND SYSTEM FOR INTEGRATED AND CONTINUOUS VIRAL FILTRATION, CONCENTRATION AND BUFFER EXCHANGE | MOAZZAMI, NAGHMEH NINA | 1652 | §102§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18561842 | TITER METHOD USING UV MEASUREMENT FOR CONTINUOUS BIOLOGICAL PRODUCTION | LEE, BYUNG RO | — | §101§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BARSKY, JARED | 1628 | DP | Final Rejection | — | Pending | Oct 24, 2023 |
| 18554231 | ANTICANCER THERAPY | JARRELL, NOBLE E | 1699 | §103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18474419 | Use of Biomarkers in the Treatment of Fibrotic Conditions with a PDE4B-inhibitor | MACFARLANE, STACEY NEE | 1675 | §101§112 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18551553 | Pharmaceutical Combinations for Treating Cancer | DRISCOLL, MAUREEN VARINA | 1644 | §112DP | Final Rejection | — | Pending | Sep 20, 2023 |
| 18468885 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | 22d | Pending | Sep 18, 2023 |
| 18461850 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | CRAIGO, BAHAR ALAWI | 1699 | DP | Final Rejection | — | Pending | Sep 06, 2023 |
| 18275616 | ANTI-IL1RAP ANTIBODIES | NICKOL, GARY B | 1643 | §102§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | MCCOLLUM, ANDREA K | 1674 | §103§112Other | Non-Final OA | 44d overdue | Pending | Jul 17, 2023 |
| 18259098 | VIRAL CAPSID PROTEINS WITH SPECIFICITY TO HEART TISSUE CELLS | GIBBS, TERRA C | 1635 | §103§112 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 18267795 | BIFUNCTIONAL ANTI-PD1/IL-7 MOLECULES | ROONEY, NORA MAUREEN | 1641 | §102§103§112Other | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18334454 | PERFUSION MEDIUM | BARRON, SEAN C | 1653 | §103 | Final Rejection | 70d | Pending | Jun 14, 2023 |
| 18256777 | FORMULATION FOR MULTI-PURPOSE APPLICATION | LU, CHENG | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | MIDDLETON, DANAYA L | 1618 | §112 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18039433 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BRANDT, DAVID NELSON | 3783 | §102§103§112 | Final Rejection | 30d | Pending | May 30, 2023 |
| 18251562 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103§112DP | Non-Final OA | — | Pending | May 03, 2023 |
| 18032634 | ADMINISTRATION DEVICE FOR IN PARTICULAR INTRAVITREAL ADMINISTRATION OF A FLUID | BOSQUES, EDELMIRA | 3772 | §102 | Final Rejection | — | Pending | Apr 19, 2023 |
| 18001980 | A METHOD OF PROVIDING A HOMOGENEOUS FEED STREAM WITHIN A PLUG FLOW REACTOR | HUANG, RYAN | 1777 | §102 | Final Rejection | — | Pending | Dec 15, 2022 |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | SHIN, DANA H | 1635 | §101§102§103§112 | Non-Final OA | 23d overdue | Pending | Nov 17, 2022 |
| 17785427 | BIFUNCTIONAL MOLECULES COMPRISING AN IL-7 VARIANT | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Jun 15, 2022 |
| 17686880 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | TIEN, LUCY MINYU | 1612 | §103§112DP | Final Rejection | 56d overdue | Pending | Mar 04, 2022 |
| 17530559 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | KASSA, TIGABU | 1619 | §103 | Final Rejection | 72d overdue | Pending | Nov 19, 2021 |
| 17525433 | CELL ENGINEERING USING RNAs | HOLLAND, PAUL J | 1656 | §103 | Non-Final OA | 34d | Pending | Nov 12, 2021 |
| 13885646 | AGENTS AND METHODS FOR TREATING DISEASES THAT CORRELATE WITH BCMA EXPRESSION | HUYNH, PHUONG N | 1641 | §103§112 | Non-Final OA | — | Pending | Jul 08, 2013 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial